- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.04. | BioSig Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.04. | BioSig Technologies, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 31.03. | BioSig Technologies, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
| 26.03. | BioSig Technologies, Inc.: BioSig Technologies Confirms Full Compliance with Nasdaq Requirements for Continued Listing on The Nasdaq Capital Market | 115 | GlobeNewswire (Europe) | Los Angeles, CA, March 26, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (BSGM) ("BioSig" or the "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac... ► Artikel lesen | |
| 25.03. | BioSig Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.03. | BioSig Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.01. | BioSig Technologies, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| BIOSIG TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 31.12.24 | BioSig Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.12.24 | BioSig Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.12.24 | BioSig Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11.24 | BioSig Technologies, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11.24 | BioSig Technologies, Inc.: BioSig Regains Compliance with Nasdaq's Minimum Bid Price Requirement | 93 | GlobeNewswire (Europe) | Los Angeles, CA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to... ► Artikel lesen | |
| 13.11.24 | BioSig Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.10.24 | BioSig Faces NASDAQ Delisting Over Price Deficiency | 1 | Investing.com | ||
| 29.10.24 | BioSig droht Delisting von der NASDAQ aufgrund zu niedriger Aktienkurse | 1 | Investing.com Deutsch | ||
| 29.10.24 | BioSig Technologies, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.10.24 | BioSig Technologies, Inc.: BioSig Technologies' Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel | 116 | GlobeNewswire (Europe) | Los Angeles, CA, Oct. 22, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) ("BioSig" or the "Company"), a medical technology company delivering unprecedented accuracy and precision... ► Artikel lesen | |
| 31.07.24 | BioSig Technologies, Inc.: BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation | 187 | GlobeNewswire (Europe) | Los Angeles, July 31, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac... ► Artikel lesen | |
| 25.07.24 | BioSig Technologies, Inc.: BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024 | 126 | GlobeNewswire (Europe) | Los Angeles, CA 90025, July 25, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) or ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision... ► Artikel lesen | |
| 10.06.24 | BioSig Technologies, Inc.: BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer | 182 | GlobeNewswire (Europe) | Westport, CT, June 10, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to... ► Artikel lesen |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,133 | +0,76 % | Sernova Aktie: Positives Umsatzwachstum gemeldet! | Das Biotechnologieunternehmen erweitert sein Führungsteam, sichert Finanzierungen und erhält FDA-Freigabe für klinische Studien zur Behandlung von Hypothyreose. Sernova Biotherapeutics, ehemals Sernova... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,639 | -0,93 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio | SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast... ► Artikel lesen | |
| PING AN HEALTHCARE | 0,800 | 0,00 % | Ping An Healthcare and Technology Company Limited: Ping An Health Reports 25.8% Year-on-Year Revenue Growth in Q1 2025, with Profitability Accelerating | Revenue and Profit Surge, Driven by "AI + Health Care" Value Empowerment
SHANGHAI and HONG KONG, April 24, 2025 /PRNewswire/ -- Ping An Healthcare and Technology... ► Artikel lesen | |
| MOUNTAIN VALLEY MD | 0,012 | 0,00 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
| CO-DIAGNOSTICS | 0,312 | -0,64 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
| CYTOSORBENTS | 0,972 | -4,14 % | CytoSorbents Gains $1.7M Via NJEDA Tax Credit Sale To Fund Strategic Growth | ||
| VERU | 0,468 | -3,70 % | Veru Aktie: Bedeutet das eine Neuausrichtung? | Die Veru-Aktie verliert weiter an Wert, doch Analysten bleiben optimistisch aufgrund vielversprechender Medikamentenentwicklungen. Wird der Tiefpunkt bald erreicht? Die Veru-Aktie setzt ihre Abwärtsspirale... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 7,050 | -100,00 % | Tempest Therapeutics: Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP | BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics... ► Artikel lesen | |
| VOLITIONRX | 0,482 | 0,00 % | VOLITIONRX LTD - 8-K, Current Report | ||
| EKSO BIONICS | 0,360 | -4,76 % | Ekso Bionics Holdings, Inc.: Bionic P&O Chosen as First Distributor of Ekso Indego Personal Within the Orthotics & Prosthetics Industry | ||
| IMUNON | 0,795 | +1,27 % | Imunon, Inc.: IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting | ||
| BEYOND AIR | 0,190 | +3,26 % | Beyond Air: NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism | The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug candidate... ► Artikel lesen | |
| AVINGER | - | - | Avinger, Inc.: Avinger Reports Third Quarter 2024 Results | Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company... ► Artikel lesen | |
| FRESENIUS | 39,850 | +0,94 % | BARCLAYS stuft Fresenius SE auf 'Overweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Fresenius von 44,00 auf 43,50 Euro gesenkt, aber die Einstufung auf "Overweight" belassen. Die Bad Homburger dürften... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 45,880 | +0,55 % | EQS-DD: Siemens Healthineers AG: Darleen Caron, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
22.04.2025 / 17:45... ► Artikel lesen |
Das Unternehmen BIOSIG TECHNOLOGIES INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,839 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOSIG TECHNOLOGIES INC finden Sie auf Wallstreet Online.
